GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Current Ratio

BLFS (BioLife Solutions) Current Ratio : 4.54 (As of Dec. 2024)


View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BioLife Solutions's current ratio for the quarter that ended in Dec. 2024 was 4.54.

BioLife Solutions has a current ratio of 4.54. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for BioLife Solutions's Current Ratio or its related term are showing as below:

BLFS' s Current Ratio Range Over the Past 10 Years
Min: 2.86   Med: 4.06   Max: 19.37
Current: 4.54

During the past 13 years, BioLife Solutions's highest Current Ratio was 19.37. The lowest was 2.86. And the median was 4.06.

BLFS's Current Ratio is ranked better than
72.7% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: 2.575 vs BLFS: 4.54

BioLife Solutions Current Ratio Historical Data

The historical data trend for BioLife Solutions's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Current Ratio Chart

BioLife Solutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.37 2.95 3.11 2.86 4.54

BioLife Solutions Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 2.89 2.86 2.78 4.54

Competitive Comparison of BioLife Solutions's Current Ratio

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions's Current Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Current Ratio distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Current Ratio falls into.


;
;

BioLife Solutions Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

BioLife Solutions's Current Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Current Ratio (A: Dec. 2024 )=Total Current Assets (A: Dec. 2024 )/Total Current Liabilities (A: Dec. 2024 )
=148.761/32.734
=4.54

BioLife Solutions's Current Ratio for the quarter that ended in Dec. 2024 is calculated as

Current Ratio (Q: Dec. 2024 )=Total Current Assets (Q: Dec. 2024 )/Total Current Liabilities (Q: Dec. 2024 )
=148.761/32.734
=4.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions  (NAS:BLFS) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


BioLife Solutions Current Ratio Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Executives
Sarah Aebersold officer: VP, Global Human Resources BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman officer: Chief Financial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Aby J. Mathew officer: Chief Tech. Officer & Sr. VP 3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard officer: Vice President, Marketing 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster officer: Vice President of Operations C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Amy Duross director 8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Greef Roderick De director
Garrie Richardson officer: Chief Revenue Officer 3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Geraint Phillips officer: SVP, Global Operations 3303 MONTE VILLA, #310, BOTHELL WA 98021
Michael Rice director, officer: President & CEO C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Marcus Schulz officer: Vice President, Global Sales 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick director 16719 NE 139TH PLACE, WOODINVILLE WA 98072
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami director SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023